The Therapeutic Significance of Concomitant Antitumor Immunity. I. LY-1-2+ T Cells from Mice with a Progressive Tumor Can Cause Regression of an Established Tumor in Gamma-irradiated Recipients

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 1984 Jan 1

PMID 6334549

Citations 14

Authors

R J NORTH

Affiliations

Soon will be listed here.

Abstract

It is shown that progressive growth of the SA1 sarcoma in its semisyngeneic AB6F1 host results in the generation of concomitant immunity to growth of a tumor challenge implant, and in the generation of T cells in the spleen capable, on passive transfer, of causing regression of an established tumor in gamma-irradiated recipients, but not in normal recipients. T cells that passively transferred concomitant immunity against an established tumor were first generated around day 6 of tumor growth, reached peak numbers on day 9, and slowly decreased in number thereafter. They were of the Ly-1-2+ phenotype, in that they were functionally eliminated by treatment with monoclonal anti-Ly-2 antibody and complement, but not by treatment with anti-Ly-1 antibody and complement. The paradoxical ability of T cells from a donor with a relatively large tumor to cause the regression of a tumor in sublethally gamma-irradiated recipients is explained with reference to the facts that the recipient tumor was only half as large as the donor tumor at the time of passive transfer, and that the recipient was incapable of generating suppressor T cells that would function to inhibit the expression of adoptive immunity.

Citing Articles

Tumor reductive therapies and antitumor immunity.

Guo H, Tsung K Oncotarget. 2017; 8(33):55736-55749.

PMID: 28903456 PMC: 5589695. DOI: 10.18632/oncotarget.18469.

In situ vaccine, immunological memory and cancer cure.

Tsung K, Norton J Hum Vaccin Immunother. 2015; 12(1):117-9.

PMID: 26360526 PMC: 4962727. DOI: 10.1080/21645515.2015.1073427.

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

Antony P, Restifo N J Immunother. 2005; 28(2):120-8.

PMID: 15725955 PMC: 1242172. DOI: 10.1097/01.cji.0000155049.26787.45.

Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression.

Zhou G, Lu Z, McCadden J, Levitsky H, Marson A J Exp Med. 2004; 200(12):1581-92.

PMID: 15596524 PMC: 2211996. DOI: 10.1084/jem.20041240.

Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors.

Rakhmilevich A, Turner J, Ford M, McCabe D, Sun W, Sondel P Proc Natl Acad Sci U S A. 1996; 93(13):6291-6.

PMID: 8692808 PMC: 39015. DOI: 10.1073/pnas.93.13.6291.

References

Gorelik E . Concomitant tumor immunity and the resistance to a second tumor challenge. Adv Cancer Res. 1983; 39:71-120. DOI: 10.1016/s0065-230x(08)61033-7. View

Eberlein T, Rosenstein M, Rosenberg S . Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med. 1982; 156(2):385-97. PMC: 2186754. DOI: 10.1084/jem.156.2.385. View

NORTH R . The therapeutic significance of concomitant antitumor immunity. II. Passive transfer of concomitant immunity with Ly-1+2- T cells primes established tumors in T cell-deficient recipients for endotoxin-induced regression. Cancer Immunol Immunother. 1984; 18(2):75-9. PMC: 11039091. DOI: 10.1007/BF00205737. View

Loveland B, McKenzie I . Cells mediating graft rejection in the mouse. II. The Ly phenotypes of cells producing tumor allograft rejection. Transplantation. 1982; 33(2):174-80. DOI: 10.1097/00007890-198202000-00013. View

NORTH R . Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells. Cancer Immunol Immunother. 1984; 16(3):175-81. PMC: 11039020. DOI: 10.1007/BF00205425. View

NORTH R, Bursuker I . Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med. 1984; 159(5):1295-311. PMC: 2187300. DOI: 10.1084/jem.159.5.1295. View

TUTTLE R, Knick V, Stopford C, Wolberg G . In vivo and in vitro antitumor activity expressed by cells of concomitantly immune mice. Cancer Res. 1983; 43(6):2600-5. View

Rouse B, Wagner H . The in vivo activity of in vitro immunized mouse thymocytes. II. Rejection of skin allografts and graft-vs-host activity. J Immunol. 1972; 109(6):1282-9. View

TYLER J, Galli S, Snider M, Dvorak A, Steinmuller D . Cloned LYT-2+ cytolytic T lymphocytes destroy allogeneic tissue in vivo. J Exp Med. 1984; 159(1):234-43. PMC: 2187201. DOI: 10.1084/jem.159.1.234. View

10.

Mills C, NORTH R . Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells. J Exp Med. 1983; 157(5):1448-60. PMC: 2187010. DOI: 10.1084/jem.157.5.1448. View

11.

Vaage J . Concomitant immunity and specific depression of immunity by residual or reinjected syngeneic tumor tissue. Cancer Res. 1971; 31(11):1655-62. View

12.

Engers H, SORENSON G, TERRES G, Horvath C, BRUNNER K . Functional activity in vivo of effector T cell populations. I. Antitumor activity exhibited by allogeneic mixed leukocyte culture cells. J Immunol. 1982; 129(3):1292-8. View

13.

Loveland B, McKenzie I . Which T cells cause graft rejection?. Transplantation. 1982; 33(3):217-21. DOI: 10.1097/00007890-198203000-00001. View

14.

Leclerc J, CANTOR H . T cell-mediated immunity to oncornavirus-induced tumors. II. Ability of different T cell sets to prevent tumor growth in vivo. J Immunol. 1980; 124(2):851-4. View

15.

NORTH R, Dye E, Mills C, CHANDLER J . Modulation of antitumor immunity--immunobiologic approaches. Springer Semin Immunopathol. 1982; 5(2):193-220. DOI: 10.1007/BF00199796. View

16.

Loveland B, Hogarth P, Ceredig R, McKenzie I . Cells mediating graft rejection in the mouse. I. Lyt-1 cells mediate skin graft rejection. J Exp Med. 1981; 153(5):1044-57. PMC: 2186155. DOI: 10.1084/jem.153.5.1044. View

17.

RUSSELL S, Doe W, McIntosh A . Functional characterization of a stable, noncytolytic stage of macrophage activation in tumors. J Exp Med. 1977; 146(6):1511-20. PMC: 2181899. DOI: 10.1084/jem.146.6.1511. View

18.

LANNIN D, Yu S, McKHANN C . Thymus-dependent response: too little and too late for immunosurveillance. Transplantation. 1982; 33(1):99-100. View

19.

Dye E, NORTH R . Adoptive immunization against an established tumor with cytolytic versus memory T cells. Immediate versus delayed onset of regression. Transplantation. 1984; 37(6):600-5. DOI: 10.1097/00007890-198406000-00015. View

20.

Ledbetter J, Rouse R, Micklem H, Herzenberg L . T cell subsets defined by expression of Lyt-1,2,3 and Thy-1 antigens. Two-parameter immunofluorescence and cytotoxicity analysis with monoclonal antibodies modifies current views. J Exp Med. 1980; 152(2):280-95. PMC: 2185937. DOI: 10.1084/jem.152.2.280. View